drugset / Trial / NCT05374915
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single cohort study to confirm dose, assessments and timing of response, to support future studies. The primary objective of the trial is to evaluate cutaneous tumor response within total target treatment field to REM-001 therapy assessed using standardized digital photography
Timeline
- Start
- 2024-02-12
- Primary completion
- 2025-12-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REM-001 | Unknown | 0.8 mg/kg | Intravenous |